Aim To conduct a systematic review of observational studies to explore the real‐world
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …

Background A precision medicine approach in type 2 diabetes requires the identification of
clinical and biological features that are reproducibly associated with differences in clinical …

Abstract Dipeptidyl peptidase-4 inhibitors (DPP-4is) and sodium-glucose cotransporter type
2 inhibitors (SGLT2is) offer new options for the oral management of type 2 diabetes mellitus …

Aims Patients with type 2 diabetes (T2D) who undergo percutaneous coronary intervention
(PCI) are at higher risk of adverse cardiovascular and renal events than non-diabetic …

Background Despite the overall improvement in care, people with type 2 diabetes (T2D)
experience an excess risk of end-stage kidney disease. We evaluated the long-term …

Background Contemporary guidelines recommend the use of sodium-glucose cotransporter
2 inhibitors (SGLT2is) independently of glycemic control in patients with type 2 diabetes and …

Aim To determine the absolute risk reduction (ARR) of heart failure events in people treated
with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors. Materials and Methods We …

Background: A precision medicine approach in type 2 diabetes requires identification of
clinical and biological features that are reproducibly associated with differences in clinical …

With increasing population aging and prevalence of type 2 diabetes (T2D) worldwide,
prevention of diabetic complications remains a major unmet need. While cardiovascular …

Aims To confirm the reno‐protective effects of sodium‐glucose cotransporter‐2 (SGLT2)
inhibitors compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors on the onset and …